Search Results

FBC SUPPORTS PATH FORWARD FOR XLRP TREATMENT

Fighting Blindness Canada is urging Johnson & Johnson to continue pursuing regulatory approval for botaretigene sparoparvovec (bota-vec), a gene therapy for X-linked retinitis pigmentosa (XLRP). This potential treatment has offered new hope...

DIABETIC RETINOPATHY

Diabetic retinopathy (DR) is the most common form of vision loss associated with diabetes, affecting approximately one million Canadians. Learn about DR.

GLAUCOMA

Glaucoma is a group of eye diseases that damage the optic nerve, often due to increased intraocular pressure (IOP). It's a leading cause of irreversible vision loss in Canada, affecting over 400,000 Canadians. Learn more.

INHERITED RETINAL DISEASES

Over 22,000 Canadians live with inherited retinal diseases (IRDs)—genetic conditions that can lead to vision loss or blindness. Fighting Blindness Canada (FBC) is at the forefront of advancing research, treatments, and support for individuals affected by IRDs. Learn more.

PROTECTING VISION RESEARCH IN THE FACE OF POTENTIAL U.S. CUTBACKS

By Jennifer Jones, President and CEO, Fighting Blindness Canada The uncertainty surrounding tariffs and research funding cuts in the United States is sending shockwaves through the global scientific community. The U.S. has...

AGE-RELATED MACULAR DEGENERATION

Age-related macular degeneration (AMD) is the leading cause of vision loss in people aged 55+, affecting 2.5 million Canadians. Learn about AMD.